Tenax Therapeutics, Inc. (TENX)
USD 5.8
(-3.33%)
USD 5.8
(-3.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.71 Million USD | 30.18% |
| 2022 | -11.04 Million USD | 66.26% |
| 2021 | -32.73 Million USD | -231.57% |
| 2020 | -9.87 Million USD | -17.59% |
| 2019 | -8.39 Million USD | -24.66% |
| 2018 | -6.73 Million USD | 23.83% |
| 2017 | -8.83 Million USD | 79.88% |
| 2016 | -43.92 Million USD | -211.92% |
| 2015 | -14.08 Million USD | 27.94% |
| 2014 | -19.54 Million USD | -107.54% |
| 2013 | -9.41 Million USD | 40.07% |
| 2012 | -15.71 Million USD | -50.38% |
| 2011 | -10.44 Million USD | 0.56% |
| 2010 | -10.5 Million USD | 68.37% |
| 2009 | -33.21 Million USD | -394.24% |
| 2008 | -6.72 Million USD | -101.78% |
| 2007 | -3.33 Million USD | 18.09% |
| 2006 | -4.06 Million USD | -52.15% |
| 2005 | -2.67 Million USD | -18.83% |
| 2004 | -2.24 Million USD | -0.98% |
| 2003 | -2.22 Million USD | 36.14% |
| 2002 | -3.48 Million USD | -108.57% |
| 2001 | -1.67 Million USD | -83.49% |
| 2000 | -911.33 Thousand USD | -13.92% |
| 1999 | -800 Thousand USD | 37.55% |
| 1998 | -1.28 Million USD | 32.94% |
| 1997 | -1.91 Million USD | 18.58% |
| 1996 | -2.34 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 3.79 Million USD | 217.77% |
| 2024 Q2 | -3.57 Million USD | -194.13% |
| 2023 Q4 | -3.22 Million USD | -63.57% |
| 2023 Q2 | -1.1 Million USD | 74.58% |
| 2023 FY | -7.71 Million USD | 30.18% |
| 2023 Q3 | -1.97 Million USD | -78.24% |
| 2023 Q1 | -4.35 Million USD | -71.06% |
| 2022 Q4 | -2.54 Million USD | 70.92% |
| 2022 Q1 | -8.16 Million USD | -154.22% |
| 2022 Q2 | -8.58 Million USD | -5.17% |
| 2022 FY | -11.04 Million USD | 66.26% |
| 2022 Q3 | -8.75 Million USD | -1.94% |
| 2021 Q3 | -3.79 Million USD | -121.24% |
| 2021 FY | -32.73 Million USD | -231.57% |
| 2021 Q4 | -3.21 Million USD | 15.48% |
| 2021 Q1 | -23.74 Million USD | -739.23% |
| 2021 Q2 | -1.71 Million USD | 92.77% |
| 2020 Q3 | -2.22 Million USD | -3.44% |
| 2020 Q4 | -2.82 Million USD | -27.44% |
| 2020 Q1 | -2.65 Million USD | 4.91% |
| 2020 FY | -9.87 Million USD | -17.59% |
| 2020 Q2 | -2.14 Million USD | 19.14% |
| 2019 Q1 | -1.61 Million USD | 27.51% |
| 2019 Q2 | -1.76 Million USD | -8.91% |
| 2019 FY | -8.39 Million USD | -24.66% |
| 2019 Q4 | -2.79 Million USD | -25.54% |
| 2019 Q3 | -2.22 Million USD | -26.24% |
| 2018 FY | -6.73 Million USD | 23.83% |
| 2018 Q3 | -1.53 Million USD | 18.2% |
| 2018 Q1 | -1.17 Million USD | 12.19% |
| 2018 Q2 | -1.87 Million USD | -58.6% |
| 2018 Q4 | -2.23 Million USD | -45.76% |
| 2017 Q1 | -3.27 Million USD | 88.95% |
| 2017 FY | -8.83 Million USD | 79.88% |
| 2017 Q4 | -1.34 Million USD | -8.88% |
| 2017 Q3 | -1.23 Million USD | 58.67% |
| 2017 Q2 | -2.98 Million USD | 8.84% |
| 2016 Q2 | -4.64 Million USD | 13.44% |
| 2016 Q4 | -29.64 Million USD | -593.72% |
| 2016 Q3 | -4.27 Million USD | 7.92% |
| 2016 FY | -43.92 Million USD | -211.92% |
| 2016 Q1 | -5.36 Million USD | -19.3% |
| 2015 FY | -14.08 Million USD | 27.94% |
| 2015 Q1 | -4.98 Million USD | -73.87% |
| 2015 Q2 | -3.03 Million USD | 39.15% |
| 2015 Q3 | -3.52 Million USD | -16.14% |
| 2015 Q4 | -4.49 Million USD | -27.52% |
| 2014 Q3 | -4.05 Million USD | -86.74% |
| 2014 Q2 | -2.17 Million USD | 79.15% |
| 2014 Q1 | -10.41 Million USD | -210.78% |
| 2014 FY | -19.54 Million USD | -107.54% |
| 2014 Q4 | -2.86 Million USD | 29.26% |
| 2013 Q3 | -3.53 Million USD | -57.29% |
| 2013 Q1 | -1.85 Million USD | 22.96% |
| 2013 FY | -9.41 Million USD | 40.07% |
| 2013 Q4 | -3.35 Million USD | 5.11% |
| 2013 Q2 | -2.24 Million USD | -20.78% |
| 2012 Q3 | -1.55 Million USD | 56.58% |
| 2012 Q4 | -2.41 Million USD | -54.95% |
| 2012 Q1 | -2.61 Million USD | 64.17% |
| 2012 Q2 | -3.58 Million USD | -37.16% |
| 2012 FY | -15.71 Million USD | -50.38% |
| 2011 Q4 | -7.29 Million USD | -149.11% |
| 2011 FY | -10.44 Million USD | 0.56% |
| 2011 Q3 | -2.92 Million USD | -2.11% |
| 2011 Q2 | -2.86 Million USD | -0.68% |
| 2011 Q1 | -2.84 Million USD | -12.02% |
| 2010 FY | -10.5 Million USD | 68.37% |
| 2010 Q1 | -2.76 Million USD | -0.51% |
| 2010 Q2 | -3 Million USD | -8.47% |
| 2010 Q3 | -2.05 Million USD | 31.65% |
| 2010 Q4 | -2.54 Million USD | -23.99% |
| 2009 Q1 | -16.7 Million USD | -99.87% |
| 2009 FY | -33.21 Million USD | -394.24% |
| 2009 Q4 | -2.75 Million USD | -6.35% |
| 2009 Q3 | -2.58 Million USD | -8.03% |
| 2009 Q2 | -2.39 Million USD | 85.65% |
| 2008 FY | -6.72 Million USD | -101.78% |
| 2008 Q4 | -8.35 Million USD | -113.61% |
| 2008 Q3 | -3.91 Million USD | 7.91% |
| 2008 Q2 | -4.24 Million USD | -74.35% |
| 2008 Q1 | -2.43 Million USD | -4.78% |
| 2007 Q1 | -1.03 Million USD | -15.92% |
| 2007 Q4 | -2.32 Million USD | -149.52% |
| 2007 FY | -3.33 Million USD | 18.09% |
| 2007 Q3 | -931.93 Thousand USD | 9.28% |
| 2007 Q2 | -1.02 Million USD | 0.58% |
| 2006 Q4 | -891.28 Thousand USD | -28.18% |
| 2006 FY | -4.06 Million USD | -52.15% |
| 2006 Q1 | -916.62 Thousand USD | -6.52% |
| 2006 Q2 | -711.07 Thousand USD | 22.43% |
| 2006 Q3 | -695.31 Thousand USD | 2.22% |
| 2005 Q3 | -1.67 Million USD | -173.88% |
| 2005 Q1 | -710.92 Thousand USD | 19.99% |
| 2005 Q4 | -860.53 Thousand USD | 48.69% |
| 2005 Q2 | -612.34 Thousand USD | 13.87% |
| 2005 FY | -2.67 Million USD | -18.83% |
| 2004 Q4 | -888.49 Thousand USD | -48.09% |
| 2004 Q1 | -523.53 Thousand USD | 35.63% |
| 2004 Q2 | -473.42 Thousand USD | 9.57% |
| 2004 FY | -2.24 Million USD | -0.98% |
| 2004 Q3 | -599.95 Thousand USD | -26.73% |
| 2003 Q1 | -335.46 Thousand USD | 27.78% |
| 2003 Q2 | -451.91 Thousand USD | -34.71% |
| 2003 Q3 | -460.42 Thousand USD | -1.88% |
| 2003 FY | -2.22 Million USD | 36.14% |
| 2003 Q4 | -813.33 Thousand USD | -76.65% |
| 2002 Q3 | -1.02 Million USD | -156.67% |
| 2002 FY | -3.48 Million USD | -108.57% |
| 2002 Q4 | -464.49 Thousand USD | 54.78% |
| 2002 Q2 | -400.19 Thousand USD | 79.66% |
| 2002 Q1 | -1.96 Million USD | -308.58% |
| 2001 FY | -1.67 Million USD | -83.49% |
| 2001 Q1 | -503.15 Thousand USD | -23.64% |
| 2001 Q2 | -517.37 Thousand USD | -2.82% |
| 2001 Q3 | -521.77 Thousand USD | -0.85% |
| 2001 Q4 | -481.46 Thousand USD | 7.73% |
| 2000 Q2 | -253.68 Thousand USD | 18.52% |
| 2000 Q4 | -406.95 Thousand USD | 19.96% |
| 2000 Q3 | -508.45 Thousand USD | -100.43% |
| 2000 FY | -911.33 Thousand USD | -13.92% |
| 2000 Q1 | -311.33 Thousand USD | -55.67% |
| 1999 Q1 | -220 Thousand USD | -46.67% |
| 1999 Q2 | -100 Thousand USD | 54.55% |
| 1999 Q3 | -200 Thousand USD | -100.0% |
| 1999 FY | -800 Thousand USD | 37.55% |
| 1999 Q4 | -200 Thousand USD | 0.0% |
| 1998 Q1 | -540 Thousand USD | -260.0% |
| 1998 Q4 | -150 Thousand USD | 37.5% |
| 1998 FY | -1.28 Million USD | 32.94% |
| 1998 Q3 | -240 Thousand USD | -4.35% |
| 1998 Q2 | -230 Thousand USD | 57.41% |
| 1997 Q2 | -210 Thousand USD | 63.16% |
| 1997 Q3 | -380 Thousand USD | -80.95% |
| 1997 FY | -1.91 Million USD | 18.58% |
| 1997 Q4 | -150 Thousand USD | 60.53% |
| 1997 Q1 | -570 Thousand USD | -72.73% |
| 1996 FY | -2.34 Million USD | 0.0% |
| 1996 Q4 | -330 Thousand USD | 51.47% |
| 1996 Q3 | -680 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 94.733% |
| Alkermes plc | 355.75 Million USD | 102.167% |
| Agenus Inc. | -245.76 Million USD | 96.863% |
| Aptorum Group Limited | -2.82 Million USD | -172.978% |
| Ardelyx, Inc. | -66.06 Million USD | 88.329% |
| Dyadic International, Inc. | -6.79 Million USD | -13.468% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -723.79% |
| Lantern Pharma Inc. | -15.96 Million USD | 51.692% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 59.479% |
| Novavax, Inc. | -545.06 Million USD | 98.585% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 86.773% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 89.551% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 58.424% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 22.785% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 86.927% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 97.936% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 68.32% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 79.35% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 95.315% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 89.487% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 62.0% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 87.614% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 76.264% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 94.18% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 98.249% |
| AlloVir, Inc. | -190.41 Million USD | 95.951% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 96.244% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 72.899% |
| Bicycle Therapeutics plc | -180.66 Million USD | 95.732% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 95.694% |
| ChromaDex Corporation | -4.93 Million USD | -56.15% |
| Chimerix, Inc. | -82.09 Million USD | 90.608% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 82.713% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 92.446% |
| CRISPR Therapeutics AG | -153.61 Million USD | 94.98% |
| Precision BioSciences, Inc. | -61.31 Million USD | 87.425% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 95.209% |
| Fortress Biotech, Inc. | -60.63 Million USD | 87.284% |
| Fortress Biotech, Inc. | -60.63 Million USD | 87.284% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 90.548% |
| ImmuCell Corporation | -5.77 Million USD | -33.527% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 93.174% |
| Immix Biopharma, Inc. | -15.42 Million USD | 50.015% |
| Incyte Corporation | 597.59 Million USD | 101.29% |
| Innoviva, Inc. | 179.72 Million USD | 104.29% |
| IO Biotech, Inc. | -86.08 Million USD | 91.043% |
| Jaguar Health, Inc. | -41.3 Million USD | 81.33% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 94.96% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 114.784% |
| ContextLogic Inc. | -317 Million USD | 97.568% |
| MiMedx Group, Inc. | 67.43 Million USD | 111.434% |
| MEI Pharma, Inc. | 17.77 Million USD | 143.372% |
| NextCure, Inc. | -62.72 Million USD | 87.707% |
| Onconetix, Inc. | -37.4 Million USD | 79.389% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 80.469% |
| Opthea Limited | -220.24 Million USD | 96.499% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 84.928% |
| Vaxcyte, Inc. | -402.26 Million USD | 98.083% |
| PDS Biotechnology Corporation | -42.94 Million USD | 82.044% |
| Precigen, Inc. | -95.9 Million USD | 91.96% |
| Pharming Group N.V. | -10.54 Million USD | 26.899% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 96.175% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 68.583% |
| PureTech Health plc | -65.69 Million USD | 88.263% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 69.269% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 96.367% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 68.32% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 97.009% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 71.691% |
| Acelyrin, Inc. | -381.64 Million USD | 97.98% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -61375.433% |
| Summit Therapeutics Inc. | -614.92 Million USD | 98.746% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 77.389% |
| Senti Biosciences, Inc. | -92.91 Million USD | 91.702% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 92.635% |
| Elevation Oncology, Inc. | -45.7 Million USD | 83.129% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 78.057% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 41.013% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -15.343% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 73.739% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 9.297% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 86.593% |
| Seer, Inc. | -86.27 Million USD | 91.063% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 88.491% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 88.275% |
| ESSA Pharma Inc. | -26.58 Million USD | 70.993% |
| GlycoMimetics, Inc. | -36.89 Million USD | 79.104% |
| GT Biopharma, Inc. | -7.59 Million USD | -1.496% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 96.805% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 85.15% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 110.798% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 85.832% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 84.302% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 22.488% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.654% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -114.902% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 84.898% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 96.86% |
| Aptose Biosciences Inc. | -51.2 Million USD | 84.942% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 92.156% |
| Soligenix, Inc. | -6.14 Million USD | -25.566% |
| Century Therapeutics, Inc. | -136.67 Million USD | 94.358% |
| Kura Oncology, Inc. | -152.63 Million USD | 94.948% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 91.357% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 26.83% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 1463.587% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -1255.127% |
| Autolus Therapeutics plc | -208.38 Million USD | 96.3% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 89.276% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 89.108% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 64.414% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 96.577% |
| GRI Bio, Inc. | -13.03 Million USD | 40.855% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -86.492% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 93.786% |
| IGM Biosciences, Inc. | -246.41 Million USD | 96.871% |
| INmune Bio, Inc. | -30 Million USD | 74.305% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 93.026% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 81.726% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 51.693% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 51.183% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 87.081% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 92.378% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 97.208% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 96.759% |
| Verastem, Inc. | -87.36 Million USD | 91.174% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 85.771% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 95.221% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 93.39% |
| Histogen Inc. | -10.62 Million USD | 27.402% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 46.029% |
| Surrozen, Inc. | -43.04 Million USD | 82.086% |
| Organovo Holdings, Inc. | -14.67 Million USD | 47.443% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -51.575% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 85.268% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 69.478% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 71.376% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 7.735% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 94.896% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 84.24% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 74.06% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 25.985% |
| Apollomics, Inc. | -172.6 Million USD | 95.533% |
| Amarin Corporation plc | -59.11 Million USD | 86.956% |
| Mesoblast Limited | -87.95 Million USD | 91.233% |
| Turnstone Biologics Corp. | -55.2 Million USD | 86.031% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 94.753% |
| Synaptogenix, Inc. | -6.03 Million USD | -27.692% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 52.427% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 90.117% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -60.925% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 8.23% |
| Exelixis, Inc. | 207.76 Million USD | 103.711% |
| Better Therapeutics, Inc. | -39.76 Million USD | 80.607% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 94.643% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 98.541% |
| NLS Pharmaceutics AG | -12.17 Million USD | 36.653% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 1.078% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 74.924% |
| Gritstone bio, Inc. | -138.49 Million USD | 94.432% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 88.039% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -92.769% |
| Avid Bioservices, Inc. | -140.75 Million USD | 94.522% |
| Insmed Incorporated | -749.56 Million USD | 98.971% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 49.237% |
| MediWound Ltd. | -6.71 Million USD | -14.81% |
| OmniAb, Inc. | -50.61 Million USD | 84.767% |
| Alector, Inc. | -130.39 Million USD | 94.086% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 93.22% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 85.128% |
| Zai Lab Limited | -334.62 Million USD | 97.696% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 97.62% |
| Aura Biosciences, Inc. | -76.4 Million USD | 89.909% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 96.714% |
| Immunic, Inc. | -93.61 Million USD | 91.763% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 94.326% |
| Veracyte, Inc. | -74.4 Million USD | 89.637% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -0.458% |
| FibroGen, Inc. | -284.23 Million USD | 97.287% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 70.606% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -10.123% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 59.057% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 101.859% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 65.814% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 115.65% |
| TG Therapeutics, Inc. | 12.67 Million USD | 160.848% |
| Galecto, Inc. | -38.34 Million USD | 79.893% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 59.129% |
| Fortrea Holdings Inc. | -3.4 Million USD | -126.785% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 93.912% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 55.714% |
| XBiotech Inc. | -24.55 Million USD | 68.601% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 88.039% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 87.698% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 92.166% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 64.014% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 86.03% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 98.729% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 88.703% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -13443.178% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 96.596% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 65.373% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 96.491% |
| NexImmune, Inc. | -32.34 Million USD | 76.161% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -45.854% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 45.104% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.195% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 68.165% |
| Scopus BioPharma Inc. | -11.6 Million USD | 33.585% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 93.398% |
| Ainos, Inc. | -13.77 Million USD | 44.006% |
| Pluri Inc. | -20.88 Million USD | 63.086% |
| Prothena Corporation plc | -147.02 Million USD | 94.756% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 93.229% |
| Celularity Inc. | -196.29 Million USD | 96.072% |
| Rallybio Corporation | -74.56 Million USD | 89.659% |
| Cue Biopharma, Inc. | -50.73 Million USD | 84.801% |
| MeiraGTx Holdings plc | -84.02 Million USD | 90.824% |
| Omeros Corporation | -117.81 Million USD | 93.455% |
| Humacyte, Inc. | -110.77 Million USD | 93.039% |
| Immunocore Holdings plc | -55.28 Million USD | 86.053% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 57.125% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 66.374% |
| Blueprint Medicines Corporation | -506.98 Million USD | 98.479% |
| CalciMedica, Inc. | -34.35 Million USD | 77.557% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 88.606% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 94.547% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 95.349% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 97.278% |
| Pulmatrix, Inc. | -14.12 Million USD | 45.396% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 78.092% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 90.669% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 98.398% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 92.647% |
| Cytokinetics, Incorporated | -526.24 Million USD | 98.535% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 78.62% |
| Nutriband Inc. | -5.48 Million USD | -40.569% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 80.924% |
| Vor Biopharma Inc. | -117.86 Million USD | 93.458% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.177% |
| Evogene Ltd. | -23.87 Million USD | 67.709% |
| ProKidney Corp. | -35.46 Million USD | 78.26% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 93.562% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 1.717% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 98.801% |
| CorMedix Inc. | -46.33 Million USD | 83.36% |
| BioLineRx Ltd. | -60.61 Million USD | 87.279% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 92.421% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 81.224% |
| Atai Life Sciences N.V. | -40.22 Million USD | 80.831% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 90.439% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 89.79% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 97.361% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 72.339% |
| MediciNova, Inc. | -8.57 Million USD | 10.043% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 93.745% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 7.952% |
| GeoVax Labs, Inc. | -25.96 Million USD | 70.306% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 96.777% |
| Biomea Fusion, Inc. | -117.25 Million USD | 93.424% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 98.769% |
| Mereo BioPharma Group plc | -29.46 Million USD | 73.832% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 94.966% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 96.317% |
| Absci Corporation | -110.56 Million USD | 93.026% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 74.426% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 92.353% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 96.732% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 154.748% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 96.004% |
| Allakos Inc. | -185.7 Million USD | 95.848% |
| Imunon, Inc. | -19.51 Million USD | 60.488% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 92.078% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 107.265% |
| BioAtla, Inc. | -123.46 Million USD | 93.755% |
| NLS Pharmaceutics AG | -12.17 Million USD | 36.653% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 52.042% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 97.644% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 79.132% |
| XOMA Corporation | -40.83 Million USD | 81.116% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 92.431% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 93.494% |
| aTyr Pharma, Inc. | -50.38 Million USD | 84.698% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 91.206% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 94.919% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 96.757% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 78.044% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 4.712% |
| Akari Therapeutics, Plc | -10 Million USD | 22.955% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -11352.912% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 102.738% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -15.691% |
| UroGen Pharma Ltd. | -102.24 Million USD | 92.459% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 92.78% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 0.855% |
| Orgenesis Inc. | -55.36 Million USD | 86.072% |
| Entera Bio Ltd. | -8.88 Million USD | 13.256% |
| GH Research PLC | -35.58 Million USD | 78.333% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 63.001% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 90.036% |
| Xencor, Inc. | -126.08 Million USD | 93.885% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -104.761% |
| Replimune Group, Inc. | -215.79 Million USD | 96.427% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 63.743% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 407.321% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -15.691% |
| Portage Biotech Inc. | -75.33 Million USD | 89.765% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 7.952% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 92.022% |
| OncoCyte Corporation | -27.78 Million USD | 72.245% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 42.531% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 30.669% |
| Purple Biotech Ltd. | -19.88 Million USD | 61.214% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -9.854% |
| scPharmaceuticals Inc. | -54.81 Million USD | 85.932% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 55.954% |
| HilleVax, Inc. | -123.56 Million USD | 93.76% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 23.71% |
| Tharimmune, Inc. | -9.31 Million USD | 17.259% |
| Genprex, Inc. | -30.86 Million USD | 75.014% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 96.732% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 74.378% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -332.698% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -45.594% |
| OKYO Pharma Limited | -16.82 Thousand USD | -45727.413% |
| Savara Inc. | -54.69 Million USD | 85.903% |
| Curis, Inc. | -47.41 Million USD | 83.737% |
| Daré Bioscience, Inc. | -30.16 Million USD | 74.435% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 50.077% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -38.457% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 74.138% |
| BeiGene, Ltd. | -881.7 Million USD | 99.125% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 63.789% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 98.233% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 90.234% |
| Erasca, Inc. | -125.04 Million USD | 93.834% |
| bluebird bio, Inc. | -211.91 Million USD | 96.361% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -54.198% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 104.599% |
| DBV Technologies S.A. | -72.72 Million USD | 89.398% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -54.198% |
| Moderna, Inc. | -4.71 Billion USD | 99.836% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 80.799% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -35.418% |
| Molecular Templates, Inc. | -8.12 Million USD | 5.088% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 87.231% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 93.078% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 94.303% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 83.909% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 94.548% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 95.993% |
| MacroGenics, Inc. | -9.05 Million USD | 14.874% |
| RenovoRx, Inc. | -10.23 Million USD | 24.642% |
| Adicet Bio, Inc. | -142.65 Million USD | 94.595% |
| Prime Medicine, Inc. | -198.13 Million USD | 96.108% |
| Aditxt, Inc. | -32.38 Million USD | 76.188% |
| Adagene Inc. | -18.94 Million USD | 59.303% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -5.456% |
| Quantum-Si incorporated | -95.96 Million USD | 91.965% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 93.522% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 47.107% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 105.827% |
| SciSparc Ltd. | -5.12 Million USD | -50.54% |
| Vericel Corporation | -3.18 Million USD | -142.322% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -6311.989% |
| Minerva Neurosciences, Inc. | -30 Million USD | 74.302% |
| Generation Bio Co. | -126.61 Million USD | 93.91% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 89.422% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 90.647% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 97.059% |
| Invivyd, Inc. | -198.64 Million USD | 96.118% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 97.745% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 11.235% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 133.81% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 21.909% |
| 2seventy bio, Inc. | -217.57 Million USD | 96.456% |
| ADMA Biologics, Inc. | -28.23 Million USD | 72.695% |
| Clene Inc. | -49.5 Million USD | 84.424% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 65.404% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 84.402% |
| GeoVax Labs, Inc. | -25.96 Million USD | 70.306% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 97.65% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 76.306% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 133.938% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 92.195% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 89.685% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 95.205% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 98.746% |
| Evaxion Biotech A/S | -22.12 Million USD | 65.15% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 90.45% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 96.146% |
| Trevena, Inc. | -40.28 Million USD | 80.862% |
| Surrozen, Inc. | -43.04 Million USD | 82.086% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 88.847% |
| Cingulate Inc. | -23.53 Million USD | 67.237% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -11.555% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 80.656% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 91.453% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 87.419% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 87.042% |
| Clearmind Medicine Inc. | -11.95 Million USD | 35.503% |
| Kronos Bio, Inc. | -112.67 Million USD | 93.157% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 88.857% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -303921.047% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 91.023% |
| Statera Biopharma, Inc. | -174.4 Million USD | 95.579% |
| ImmunityBio, Inc. | -583.19 Million USD | 98.678% |
| Korro Bio, Inc. | -81.17 Million USD | 90.501% |
| Kineta, Inc. | -14.09 Million USD | 45.31% |
| BioVie Inc. | -32.12 Million USD | 75.995% |
| Codexis, Inc. | -76.24 Million USD | 89.886% |
| Celularity Inc. | -196.29 Million USD | 96.072% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 96.406% |
| Celcuity Inc. | -63.77 Million USD | 87.91% |
| Virax Biolabs Group Limited | -6.73 Million USD | -14.511% |
| Cibus, Inc. | -267.62 Million USD | 97.119% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 80.879% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 78.468% |
| IN8bio, Inc. | -30 Million USD | 74.304% |
| Kodiak Sciences Inc. | -260.49 Million USD | 97.04% |
| Annexon, Inc. | -134.23 Million USD | 94.256% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 93.419% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 87.407% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 75.556% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 97.895% |
| Eyenovia, Inc. | -27.26 Million USD | 71.715% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 135.712% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1341.247% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 89.908% |
| Arcellx, Inc. | -70.69 Million USD | 89.092% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 81.394% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 94.238% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 74.329% |
| Moolec Science SA | -51.78 Million USD | 85.111% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 85.277% |
| Geron Corporation | -184.12 Million USD | 95.812% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 81.63% |
| Royalty Pharma plc | 1.13 Billion USD | 100.679% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 94.329% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 13.283% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 63.703% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 95.508% |
| Humacyte, Inc. | -110.77 Million USD | 93.039% |
| Structure Therapeutics Inc. | -89.62 Million USD | 91.396% |
| 89bio, Inc. | -142.18 Million USD | 94.577% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 88.819% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 25.695% |
| Genelux Corporation | -28.29 Million USD | 72.751% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 73.471% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 95.647% |
| Notable Labs, Ltd. | -11.26 Million USD | 31.546% |
| Liquidia Corporation | -78.5 Million USD | 90.178% |
| Mustang Bio, Inc. | -51.6 Million USD | 85.057% |
| Immunovant, Inc. | -259.33 Million USD | 97.027% |
| Quantum-Si incorporated | -95.96 Million USD | 91.965% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 89.416% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 60.215% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 91.967% |
| Acasti Pharma Inc. | -12.85 Million USD | 40.009% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 65.666% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 51.693% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 95.772% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -79.255% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 38.166% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 73.854% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 80.223% |
| PepGen Inc. | -78.62 Million USD | 90.193% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 74.098% |
| United Therapeutics Corporation | 984.8 Million USD | 100.783% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 65.361% |
| Solid Biosciences Inc. | -96.01 Million USD | 91.969% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -60.925% |
| Immuneering Corporation | -53.47 Million USD | 85.58% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -51.575% |
| Silo Pharma, Inc. | -3.7 Million USD | -108.358% |
| Belite Bio, Inc | -31.63 Million USD | 75.624% |
| XOMA Corporation | -40.83 Million USD | 81.116% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 85.817% |
| Bionomics Limited | -15.49 Billion USD | 99.95% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 90.819% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 73.555% |
| uniQure N.V. | -308.47 Million USD | 97.5% |
| Cassava Sciences, Inc. | -97.21 Million USD | 92.069% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -5.456% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 93.753% |
| Forte Biosciences, Inc. | -31.47 Million USD | 75.503% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 5.987% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 73.474% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1341.247% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 70.606% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 53.226% |
| Altimmune, Inc. | -88.44 Million USD | 91.282% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 94.913% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 73.555% |
| Compugen Ltd. | -18.75 Million USD | 58.885% |
| Peak Bio, Inc. | -1259.26 USD | -612217.79% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 83.256% |
| Benitec Biopharma Inc. | -21.75 Million USD | 64.55% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 97.724% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 90.705% |
| Zura Bio Limited | -60.36 Million USD | 87.226% |
| PolyPid Ltd. | -23.86 Million USD | 67.69% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 50.987% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 90.705% |
| Instil Bio, Inc. | -156.08 Million USD | 95.06% |
| argenx SE | -295.05 Million USD | 97.387% |
| Immunome, Inc. | -106.8 Million USD | 92.781% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 81.855% |
| Verona Pharma plc | -54.36 Million USD | 85.818% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 92.283% |
| Shattuck Labs, Inc. | -87.29 Million USD | 91.167% |
| CervoMed Inc. | -2.17 Million USD | -255.024% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 93.814% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 42.095% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 82.297% |
| Moolec Science SA | -51.78 Million USD | 85.111% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -44491.681% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 94.293% |
| AnaptysBio, Inc. | -163.61 Million USD | 95.287% |
| Design Therapeutics, Inc. | -66.86 Million USD | 88.468% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 90.529% |
| NeurAxis, Inc. | -14.62 Million USD | 47.284% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 79.646% |
| Lumos Pharma, Inc. | -34.03 Million USD | 77.344% |
| Achilles Therapeutics plc | -69.66 Million USD | 88.932% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 92.283% |
| 180 Life Sciences Corp. | -19.93 Million USD | 61.321% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 356.272% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -303921.047% |
| Nutriband Inc. | -5.48 Million USD | -40.569% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 92.343% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 84.137% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 89.998% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 77.302% |
| MoonLake Immunotherapeutics | -36 Million USD | 78.586% |
| Palisade Bio, Inc. | -12.3 Million USD | 37.312% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 81.695% |
| Beam Therapeutics Inc. | -132.52 Million USD | 94.182% |
| Neurogene Inc. | -36.31 Million USD | 78.768% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 95.282% |
| AEON Biopharma, Inc. | -52.55 Million USD | 85.329% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 92.144% |
| Sesen Bio, Inc. | -19.88 Million USD | 61.222% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 89.228% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 38.383% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 98.264% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 93.089% |
| Athira Pharma, Inc. | -117.67 Million USD | 93.447% |
| Vaccinex, Inc. | -20.25 Million USD | 61.924% |
| HCW Biologics Inc. | -24.99 Million USD | 69.15% |
| XOMA Corporation | -40.83 Million USD | 81.116% |
| Nektar Therapeutics | -276.05 Million USD | 97.207% |
| Arvinas, Inc. | -367.3 Million USD | 97.901% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -11352.912% |
| Merus N.V. | -154.93 Million USD | 95.023% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 92.086% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 75.432% |
| Rezolute, Inc. | -68.45 Million USD | 88.737% |
| Clene Inc. | -49.5 Million USD | 84.424% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 50.007% |
| BeyondSpring Inc. | -21.02 Million USD | 63.328% |
| Synlogic, Inc. | -57.28 Million USD | 86.539% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 35.21% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 28.776% |
| Peak Bio, Inc. | -1259.26 USD | -612217.79% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 79.366% |
| Krystal Biotech, Inc. | 10.93 Million USD | 170.533% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 94.612% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 97.628% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -66.935% |
| MannKind Corporation | -11.93 Million USD | 35.411% |
| Ikena Oncology, Inc. | -68.16 Million USD | 88.688% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 63.309% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 91.703% |
| Gossamer Bio, Inc. | -179.81 Million USD | 95.712% |
| CohBar, Inc. | -11.96 Million USD | 35.541% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 70.1% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 74.426% |
| Legend Biotech Corporation | -518.25 Million USD | 98.512% |
| Mural Oncology plc | -207.44 Million USD | 96.283% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 93.787% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 57.842% |
| Disc Medicine, Inc. | -76.42 Million USD | 89.911% |
| Champions Oncology, Inc. | -7.27 Million USD | -5.974% |
| REGENXBIO Inc. | -263.49 Million USD | 97.074% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 27.347% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 83.769% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 79.7% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 92.302% |
| Vaxart, Inc. | -82.46 Million USD | 90.65% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 2410.224% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 79.461% |
| Cellectis S.A. | -101.05 Million USD | 92.37% |
| Longeveron Inc. | -21.41 Million USD | 63.991% |
| Repare Therapeutics Inc. | -93.79 Million USD | 91.779% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.561% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 89.166% |
| Revolution Medicines, Inc. | -436.36 Million USD | 98.233% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -17.344% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 74.985% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 88.879% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 88.088% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 21.408% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.213% |
| Denali Therapeutics Inc. | -145.22 Million USD | 94.69% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -6311.989% |
| Veru Inc. | -93.15 Million USD | 91.723% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 71.473% |
| Cingulate Inc. | -23.53 Million USD | 67.237% |
| Passage Bio, Inc. | -102.06 Million USD | 92.445% |
| Context Therapeutics Inc. | -23.96 Million USD | 67.824% |
| Exicure, Inc. | -16.91 Million USD | 54.412% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 95.918% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 79.582% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -18.492% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 95.825% |
| Nuvalent, Inc. | -126.21 Million USD | 93.891% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 26.674% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 91.125% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 74.756% |
| OmniAb, Inc. | -50.61 Million USD | 84.767% |
| Anew Medical, Inc. | 1.34 Million USD | 672.805% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 51.943% |
| Lipocine Inc. | -16.35 Million USD | 52.846% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 88.386% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 87.891% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 81.726% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 83.925% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 61.118% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 98.576% |
| Ocugen, Inc. | -63.07 Million USD | 87.776% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 91.946% |
| Q32 Bio Inc. | -112.96 Million USD | 93.174% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 55.15% |
| Alumis Inc. Common Stock | -154.99 Million USD | 95.025% |
| Equillium, Inc. | -13.33 Million USD | 42.177% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 87.227% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 3.47% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 59.097% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 86.949% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 93.267% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 58.044% |
| Dominari Holdings Inc. | -22.88 Million USD | 66.302% |
| Edesa Biotech, Inc. | -8.37 Million USD | 7.926% |
| vTv Therapeutics Inc. | -20.25 Million USD | 61.923% |
| Bio-Techne Corporation | 168.1 Million USD | 104.587% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 97.81% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 105.984% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 93.671% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 79.676% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 93.155% |
| Nkarta, Inc. | -117.5 Million USD | 93.438% |
| BioCardia, Inc. | -11.57 Million USD | 33.362% |
| Iterum Therapeutics plc | -38.37 Million USD | 79.905% |